Opella (Aspégic) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Opella (Aspégic) General Information
Description
A pharmaceutical brand. The medicine is indicated for the treatment of pain, fever, and inflammation.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
- Neuilly-Sur-Seine
- France
Corporate Office
- Neuilly-Sur-Seine
- France
Opella (Aspégic) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Opella (Aspégic) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Opella (Aspégic) FAQs
-
Where is Opella (Aspégic) headquartered?
Opella (Aspégic) is headquartered in Neuilly-Sur-Seine, France.
-
What industry is Opella (Aspégic) in?
Opella (Aspégic)’s primary industry is Buildings and Property.
-
Is Opella (Aspégic) a private or public company?
Opella (Aspégic) is a Private company.
-
What is Opella (Aspégic)’s current revenue?
The current revenue for Opella (Aspégic) is .
-
Who are Opella (Aspégic)’s investors?
Opella has invested in Opella (Aspégic).
-
When was Opella (Aspégic) acquired?
Opella (Aspégic) was acquired on 31-Oct-2025.
-
Who acquired Opella (Aspégic)?
Opella (Aspégic) was acquired by Substipharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process